Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US1510201049
Ticker CELG
Company CELGENE
Currency $
Price
Aware Investor Index (AII) 5.5846
Recommendation BUY
P/E 35.02
ROE 29.98 %
Capitalization 64,684,470,000 $
Dividend Yield 0.00 %
P/S 4.23
AII Position 139
P/E Position 501
ROE Position 98
Capitalization Position 133
Dividend Yield Position 594
Sales 15,281,000,000 $
10-Year Average Earnings 1,846,838,900 $
Shares Outstanding 733,800,000
Equity 6,161,000,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
CELGENE Investor Relations Web Site http://ir.celgene.com







Sales:

YEAR MONTH AMOUNT
2018 12 15,281,000,000.00 $
2017 12 13,003,000,000.00 $
2016 12 11,229,000,000.00 $
2015 12 9,256,000,000.00 $
2014 12 7,670,400,000.00 $
2013 12 6,493,900,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 12 4,046,000,000.00 $
2017 12 2,940,000,000.00 $
2016 12 1,999,000,000.00 $
2015 12 1,602,000,000.00 $
2014 12 1,999,900,000.00 $
2013 12 1,449,900,000.00 $
2012 12 1,456,180,000.00 $
2011 12 1,318,150,000.00 $
2010 12 880,512,000.00 $
2009 12 776,747,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 12 6,161,000,000.00 $
2017 12 6,921,000,000.00 $
2016 12 6,600,000,000.00 $
2015 12 5,919,000,000.00 $
2014 12 6,524,800,000.00 $
2013 12 5,589,900,000.00 $
2012 12 5,694,467,000.00 $
2011 12 5,512,727,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 733,800,000
2017 12 808,700,000
2016 12 803,300,000
2015 12 824,900,000
2014 12 836,000,000
2013 12 430,300,000
2012 12 440,796,000
2011 12 422,987,284

 












Bloomberg News for CELGENE:



Google News for CELGENE:

Seeking Alpha - 1 day ago
Celgene's Shareholders, Not Bristol-Myers Squibb's, Should Reject ...
When Celgene (CELG) and Bristol-Myers Squibb (BMY) announced their mega-merger just days after the new year, it shocked the entire ...
StreetInsider.com
Celgene (CELG) Dips More Than Broader Markets: What You ...
Celgene (CELG) closed the most recent trading day at $87.92, moving -0.26% from the previous trading session. This change lagged the S&P ...
Nasdaq - 15 hours ago
Celgene (CELG) Submits Application to FDA for Ozanimod for ...
Celgene Corporation (NASDAQ: CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug ...
StreetInsider.com - 18 hours ago
Celgene files US application for MS med ozanimod
Celgene (NASDAQ:CELG) has filed a marketing application with the FDA seeking approval for ozanimod for the treatment of adults with ...
Business Wire (press release)
Bristol-Myers Squibb (BMY) Receives FTC Second Request in ...
... Receives FTC Second Request in Connection with Celgene (CELG) ... in an SEC filing related to is deal with Celgene (NASDAQ: CELG):.
Seeking Alpha - 17 hours ago
Celgene Presents An Attractive Short-Term Investment Opportunity ...
The proposed cash and stock acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) saw the former's share price jump up from $66.64 ...
StreetInsider.com - 3 hours ago
Celgene/Bristol-Myers Merger: The Arb Spread Continuum Offers ...
(BMY) made an offer to acquire Celgene Corp. (CELG). Several S.A. authors contributed thoughtful commentaries reflecting upon the April 12 ...
Seeking Alpha
Celgene Corporation (CELG) Continuing Signs Of A Slowdown?
Shares of Celgene Corporation (NASDAQ:CELG) have generated a 1-year price change of 1.16%. However, a year is a very long time in the ...
TheStreet.com
Celgene-Bristol: Deal Or No Deal?
Large BMY shareholders are starting to oppose its acquisition of CELG. The uncertainty of whether the deal will go through or not is driving the ...
Seeking Alpha - 5 days ago
Starboard to Vote Against Bristol-Celgene Deal, Suggests a Sale ...
Activist investor Starboard Value said it will vote against the record pharmaceutical merger of Bristol-Myers Squibb Co. and Celgene Corp., ...


Back